At the 24th Congress of the European Hematology Association (EHA), Paul G. Richardson from the Dana-Farber Cancer Institute, Boston, US, speaks to the Multiple Myeloma Hub about the results of the phase III ICARIA-MM trial of isatuximab + pomalidomide + dexamethasone compared to standard-of-care - pomalidomide + dexamethasone - for patients with relapsed/refractory multiple myeloma (RRMM).
Prof. Richardson highlights the high quality responses to the triplet regimen in relation to overall response and the primary endpoint of progression-free survival (approximately 12 months versus 6 months).
It was also highlighted that the triplet regimen was well tolerated and did not reduce the patient's quality of life. Whilst there was a higher rate of infection in the triplet arm, these were manageable. In subgroup analysis, all subgroups benefited.
Comparing isatuximab to daratumumab, Prof. Richardson highlighted some of the differences, including isatuximab's higher specificity to a different epitope, enhancing the apoptotic signal and leading to less complement activation and therefore less infusion reactions. Additionally, this means isatuximab can be given to patients with chronic obstructive pulmonary disease (COPD) and asthma which is significant.